Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
The Lancet Regional Health. Europe（2023）
摘要
None.
更多查看译文
关键词
Cystic fibrosis,Elexacaftor/tezacaftor/ivacaftor,Lung function,Body mass index,Pulmonary exacerbation,Sweat chloride,Real-world evidence
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要